Status:
COMPLETED
A Study to Evaluate the Influence of Diet on GI Health
Lead Sponsor:
Mayo Clinic
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to understand the potential of protein and psyllium fiber to manipulate gut microbial densities, intestinal permeability, and inflammation in humans.
Eligibility Criteria
Inclusion
- Adults ≥ 18 years old
- On a baseline diet characterized by: Fiber intake of \</= 20g/day, \> 18% of daily calories from protein
Exclusion
- Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy)
- Known diagnosis of inflammatory bowel disease (Crohn's or ulcerative colitis), microscopic colitis, celiac disease, or other inflammatory GI condition
- Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability)
- Use of NSAIDs or aspirin and unable or unwilling to stop taking two weeks prior to permeability test and for the duration of the study
- Use of osmotic laxatives and unable or unwilling to stop taking one week prior to permeability test and for the duration of the study
- Use of oral corticosteroids and unable or unwilling to stop use of oral corticosteroids within the previous 6 weeks and for the duration of the study
- Multiple dietary restrictions or unable/unwilling to alter dietary protein or dietary fiber.
- Unwilling to stop ingestion of alcohol and artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days before and during the permeability testing days, e.g. foods to be avoided are sugarless gums or mints and diet beverages
- Unwilling to stop stenuous exercise (running \>5 miles or equivalent) one week prior to the permeability tests
- Bowel preparation for colonoscopy less than one week prior to completion of the first stool kit and permeability test and flexible sigmoidoscopy and upper endoscopy
- Pregnancy or plan to become pregnant during the study time frame
- Vulnerable adult
- Known bleeding disorders or takes medications that increase risk of bleeding from mucosal biopsies
- Use of oral antibiotic(s) within the past 4 weeks (can be enrolled after 4-week washout period)
- Use of commercial probiotic formulations and unwilling to stop for the duration of the study
- Diagnosis of diabetes
- Any other disease(s), condition(s) or habits(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes
Key Trial Info
Start Date :
June 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 27 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04783142
Start Date
June 11 2021
End Date
March 27 2023
Last Update
May 15 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
2
Mayo Clinic
Rochester, Minnesota, United States, 55905